Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T09:17:58.577Z Has data issue: false hasContentIssue false
  • English
  • Français

The DRD2/ANKK1 Taq1A polymorphism in CYP2D6 extensive metabolizers is associated with the severity of extrapyramidal side effects of haloperidol treatment in schizophrenia spectrum disorders patients

Published online by Cambridge University Press:  13 August 2021

A. Kibitov ,
E. Kiryanova ,
L. Salnikova ,
E. Zmeyeva ,
A. Shmukler  and
A. Kibitov
A. Kibitov*
Affiliation:
Translational Psychiatry Department, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint-Petersburg, Russian Federation
E. Kiryanova
Affiliation:
Moscow Research Institute For Psychiatry, Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
L. Salnikova
Affiliation:
Moscow Research Institute For Psychiatry, Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
E. Zmeyeva
Affiliation:
Laboratory Of Molecular Genetics, Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
A. Shmukler
Affiliation:
Moscow Research Institute For Psychiatry, Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
A. Kibitov
Affiliation:
Laboratory Of Molecular Genetics, Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia is one of the most severe mental disorders. Haloperidol and other first-generation antipsychotics are widely used for schizophrenia treatment, but have prominent side effects, primarily extrapyramidal symptoms (EPS). The EPS severity is highly variable and may be underlied by genetic factors.

Objectives

We performed a prospective study to test the association of DRD2/ANKK1 Taq1A polymorphism (rs18000497) and CYP2D6 phenotype, predicted from genotypes using 8 CYP2D6 alleles (*3, *4, *5, *6,*9, *10,*41, xN) with EPS severity during haloperidol treatment in schizophrenia spectrum disorders patients.

Methods

57 inpatients with schizophrenia spectrum disorders (42,1% females; mean age - 46,7±11,8 y.o (M±SD) of European ancestry were enrolled in the study. Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), Simpson-Angus Scale (SAS) were used to assess EPS on two timepoints: day 1 and day 21 of haloperidol treatment.

Results

TaqIA T-allele carriers in contrast to wild-type allele homozygous patients had higher scores of BARS (p=0.029) and SAS (p=0.024) on day 21. After stratification by CYP2D6 phenotype, these differences were observed only in extensive metabolizers (p=0.006 and p=0.001 respectively), although the CYP2D6 phenotype itself was not associated with EPS severity. The combined effect of TaqIA T allele with CYP2D6 extensive phenotype on BARS score on day 21 was confirmed by General Linear Model (p=0.013).

Conclusions

Our results show that minor TaqIA T-allele is associated with the severity of EPS after 3 weeks of haloperidol treatment only in CYP2D6 extensive metabolizers. That highlights the importance of using both pharmacokinetic and pharmacodynamic genetic markers in pharmacogenetic EPS risk assessment.

Disclosure

No significant relationships.

Keywords

AntipsychoticsHaloperidolPharmacogenetics
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S122 - S123
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.